255 related articles for article (PubMed ID: 35395389)
1. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.
Schoutrop E; Moyano-Galceran L; Lheureux S; Mattsson J; Lehti K; Dahlstrand H; Magalhaes I
Semin Cancer Biol; 2022 Nov; 86(Pt 3):207-223. PubMed ID: 35395389
[TBL] [Abstract][Full Text] [Related]
2. The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.
Ritch SJ; Telleria CM
Front Endocrinol (Lausanne); 2022; 13():886533. PubMed ID: 35574025
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
[TBL] [Abstract][Full Text] [Related]
4. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.
Pereira M; Matuszewska K; Jamieson C; Petrik J
Front Endocrinol (Lausanne); 2021; 12():772349. PubMed ID: 34867818
[TBL] [Abstract][Full Text] [Related]
5. Basics of immunotherapy for epithelial ovarian cancer.
Bund V; Azaïs H; Bibi-Triki S; Lecointre L; Betrian SB; Angeles MA; Eberst L; Faller E; Boisramé T; Bendifallah S; Akladios C; Deluche É;
J Gynecol Obstet Hum Reprod; 2022 Feb; 51(2):102283. PubMed ID: 34875397
[TBL] [Abstract][Full Text] [Related]
6. Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.
Zhang Y; Cui Q; Xu M; Liu D; Yao S; Chen M
Front Immunol; 2022; 13():901772. PubMed ID: 35833132
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
9. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
10. The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.
Rodriguez GM; Galpin KJC; Cook DP; Yakubovich E; Maranda V; Macdonald EA; Wilson-Sanchez J; Thomas AL; Burdette JE; Vanderhyden BC
Cancer Res Commun; 2022 Jun; 2(6):417-433. PubMed ID: 36311166
[TBL] [Abstract][Full Text] [Related]
11. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
Chodon T; Lugade AA; Battaglia S; Odunsi K
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study.
Chao WT; Chien CH; Lai CR; Wu HJ; Chuang CM
Cancer Control; 2019; 26(1):1073274819863778. PubMed ID: 31343898
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in rare ovarian cancer.
Laga T; Vergote I; Van Nieuwenhuysen E
Curr Opin Oncol; 2021 Sep; 33(5):447-456. PubMed ID: 34230441
[TBL] [Abstract][Full Text] [Related]
14. The role of reproductive hormones in epithelial ovarian carcinogenesis.
Gharwan H; Bunch KP; Annunziata CM
Endocr Relat Cancer; 2015 Dec; 22(6):R339-63. PubMed ID: 26373571
[TBL] [Abstract][Full Text] [Related]
15. Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers.
Gertych A; Walts AE; Cheng K; Liu M; John J; Lester J; Karlan BY; Orsulic S
Cells; 2022 Nov; 11(23):. PubMed ID: 36497028
[TBL] [Abstract][Full Text] [Related]
16. The immunotherapy of patients with ovarian cancer.
Hwu P; Freedman RS
J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
[TBL] [Abstract][Full Text] [Related]
17. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer.
Li Y; Wang W; Wang D; Zhang L; Wang X; He J; Cao L; Li K; Xie H
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553542
[TBL] [Abstract][Full Text] [Related]
18. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux S; Braunstein M; Oza AM
CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
[TBL] [Abstract][Full Text] [Related]
19. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
20. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
Benard E; Casey NP; Inderberg EM; Wälchli S
Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
